Clinical Trials Logo

Lymphoma, Small Lymphocytic clinical trials

View clinical trials related to Lymphoma, Small Lymphocytic.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04342117 Terminated - Lymphoma Clinical Trials

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

REAL
Start date: April 23, 2020
Phase:
Study type: Observational [Patient Registry]

This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.

NCT ID: NCT02292225 Terminated - Clinical trials for Lymphocytic Leukemia, Chronic

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Start date: February 2015
Phase: Phase 1
Study type: Interventional

To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.

NCT ID: NCT01005979 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Start date: July 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD), safety and toxicity when cyclophosphamide, rituximab and lenalidomide (Revlimid) are combined for the treatment of relapsed/refractory of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

NCT ID: NCT00636155 Terminated - Clinical trials for Leukemia, Lymphocytic, Chronic

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

NCT ID: NCT00290407 Terminated - Clinical trials for Leukemia, Lymphocytic, Chronic

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.

NCT ID: NCT00083473 Terminated - Clinical trials for Leukemia, Lymphocytic, Chronic

A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot study will assess the safety and efficacy of Pivanex alone in patients with chronic lymphocytic leukemia (CLL) who have relapsed or refractory disease after previous chemotherapy treatment. Pivanex is an investigational agent.